Exogenous sex hormones and risk of breast cancer

References

• Ursin G, Ross RK, Sullivan-Halley J, Hanisch R, Henderson B, Bernstein L. Use of oral contraceptive use and risk of breast cancer in young women. Breast Cancer Res Treat 1998;50:175–184.
   PubMed Web of Science ®Google Scholar
• Anderson GL, Chlebowski RT, Rossouw JE, Rodabough RJ, McTiernan A, Margolis KL, Aggerwal A, David Curb J, Hendrix SL, Allan Hubbell F, et al Prior hormone therapy and breast cancer risk in the Women's Health Initiative randomized trial of estrogen plus progestin. Maturitas 2006;55:103–115.
   PubMed Web of Science ®Google Scholar
• Marchbanks PA, McDonald JA, Wilson HG, Folger SG, Mandel MG, Daling JR, Bernstein L, Malone KE, Ursin G, Strom BL, et al Oral contraceptives and the risk of breast cancer. N Engl J Med 2002;346:2025–2032.
   PubMed Web of Science ®Google Scholar
• Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Lancet 1997;350:1047–1059.
   PubMed Web of Science ®Google Scholar
• Ursin G, Henderson BE, Haile RW, Pike MC, Zhou N, Diep A, Bernstein L. Does oral contraceptive use increase the risk of breast cancer in women with BRCA ½ mutations more than in other women? Cancer Res 1997;57:3678–3681.
   PubMed Web of Science ®Google Scholar
• Lee E, Ma H, McKean-Cowdin R, Van Den Berg D, Bernstein L, Henderson BE., Ursin G. Effect of reproductive factors and oral contraceptives on breast cancer risk in BRCA1/2 mutation carriers and noncarriers: results from a population-based Study. Cancer Epidem Biomark Prev 2008;17:3170–3178.
   PubMed Web of Science ®Google Scholar
• Hankinson SE, Colditz GA, Manson JE, Willett WC, Hunter DJ, Stampfer MJ, Speizer FE. A prospective study of oral contraceptive use and risk of breast cancer (Nurses' Health Study US). Cancer Cases Control 1997;83:65–72.
   Google Scholar
• Casey PM, Cernan JR, Pruthi S. Oral contraceptive use and the risk of breast cancer. Mayo Clin Proc 2008;83:86–91.
   PubMedGoogle Scholar
• Foidart JM, Desreux J, Pintiaux A, Gompel A. Hormone therapy and breast cancer risk. Climacteric 2007;10:54–61.
   PubMed Web of Science ®Google Scholar
• Lech MM, Ostrowska L. Risk of cancer development in relation to oral contraception. Eur J Contracept Reprod Health Care 2006;11:162–168.
   PubMed Web of Science ®Google Scholar
• Gill JK, Press MF, Patel AV, Bernstein L. Oral contraceptive use and risk of breast carcinoma in situ (United States). Cancer Causes Control 2006;17:1155–1162.
   PubMedGoogle Scholar
• Jatoi I, Anderson WF, Rosenberg PS. Qualitative ageinteractions in breast cancer: a tale of two diseases. Am J Clin Oncol 2008;31:504–506.
   PubMedGoogle Scholar
• Vessey M, Yeates D. Oral contraceptives and benign breast disease: an update of findings in a large cohort study. Contraception 2007;76:418–424.
   PubMed Web of Science ®Google Scholar
• Salhab M, Al Sarakbi W, Mokbel K. In vitro fertilization and breast cancer risk: a review. Int J Fertil Womens Med 2005;50:259–266.
   PubMedGoogle Scholar
• Chlebowski RT, Hendrix SL, Langer RD, Stefanick ML, Gass M, Lane D, Rodabough RJ, Gilligan MA, Cyr MG, Thomson CA, Khandekar J, Petrovitch H, McTiernan A. WHI Investigators. Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative randomized trial. JAMA 2003;289:3243–3253.
   PubMed Web of Science ®Google Scholar
• Estrogen and progestogen use in postmenopausal women: July 2008 position statement of The North American Menopause Society. Menopause 2008;15:584–603.
   PubMed Web of Science ®Google Scholar
• Gompel A, Rozenberg S, Barlow DH, the EMAS board members. The EMAS 2008 update on clinical recommendations on postmenopausal hormone replacement therapy. Maturitas 2008;61:227–232.
   PubMed Web of Science ®Google Scholar
• Pines A, Sturdee DW., Birkhäuser MH., de Villiers T, Naftolin F, Gompel A, Farmer R, Barlow D, Tan D, Maki P, Lobo, Hodis H. et al on behalf of the International Menopause Society. HRT in the early menopause: scientific evidence and common perceptions. Summary of the First IMS Global Summit on menopause related issues March 29–30, 2008. Climacteric 2008;11:267–272.
   PubMed Web of Science ®Google Scholar
• Stefanick ML, Anderson GL, Margolis KL, Hendrix SL, Rodabough RJ, Paskett ED, Lane DS, Hubbell FA, Assaf AR, Sarto GE, Schenken RS, Yasmeen S, Lessin L, Chlebowski RT. WHI Investigators. Effects of conjugated equine estrogens on breast cancer and mammography screening in postmenopausal women with hysterectomy. JAMA 2006;295:1647–1657.
   PubMed Web of Science ®Google Scholar
• Chen WY, Manson JE, Hankinson SE, Rosner B, Holmes MD, Willett WC, Colditz GA. Unopposed estrogen therapy and the risk of invasive breast cancer. Arch Intern Med 2006;166:1027–1032.
   PubMed Web of Science ®Google Scholar
• Fournier A, Berrino F, Clavel-Chapelon F. Unequal risks for breast cancer associated with different hormone replacement therapies: results from the E3N cohort study. Breast Cancer Res Treat 2008;107:103–111.
   PubMed Web of Science ®Google Scholar
• Heikkinen J, Vaheri R, Timonen U. A 10-year follow-up of postmenopausal women on long-term continuous combined hormone replacement therapy: update of safety and quality-of life findings. J Br Menopause Soc 2006;12:115–125.
   PubMedGoogle Scholar
• Newcomb PA, Egan KM, Trentham-Dietz A, Titus-Ernstoff L, Baron JA, Hampton JM, Stampfer MJ, Willett WC. Prediagnostic use of hormone therapy and mortality after breast cancer. Cancer Epidemiol Biomarkers Prev 2008;17:864–871.
   PubMed Web of Science ®Google Scholar